<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandeep Gurbuxani, MBBS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geoffrey Uy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bob Lowenberg, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients who are exposed to deoxyribonucleic acid (DNA)-damaging agents, including cytotoxic chemotherapy and radiation therapy, are at risk for developing therapy-related myeloid neoplasms (t-MNs). These disorders comprise a continuum of diseases that includes acute myeloid leukemia, myelodysplastic syndromes/neoplasms (MDS), and MDS/myeloproliferative neoplasms. </p><p>Any myeloid neoplasm in a patient who previously received cytotoxic therapy for another malignancy or an autoimmune disorder is considered to have a t-MN. However, the International Classification Consensus [<a href="#rid1">1</a>] and the World Health Organization 5<sup>th</sup> edition [<a href="#rid2">2</a>] apply different labels and diagnostic criteria for t-MNs.</p><p>Certain cytogenetic and molecular changes are common in these disorders; t-MNs frequently exhibit adverse biologic features and poor outcomes. The interval from first exposure until diagnosis of a t-MN (ie, disease latency) varies with the type of agent.</p><p>This topic discusses the epidemiology, causes, evaluation, diagnosis, and classification of t-MNs.</p><p>Management and prognosis of t-MNs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H451595503"><span class="h1">DESCRIPTION</span><span class="headingEndMark"> — </span>t-MNs comprise a spectrum of myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), and MDS/myeloproliferative neoplasms (MPN). Compared with the corresponding de novo AML, MDS, or MDS/MPN, t-MNs more often exhibit adverse biologic features and resistance to treatment.</p><p>The names and diagnostic criteria for t-MNs differ between the two contemporary classification schemes: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Classification Consensus</strong> – The International Classification Consensus (ICC) describes t-MNs according to their morphologic and genetic features as either MDS, MDS/AML, AML, or MDS/MPN but adds "therapy-related" as a diagnostic qualifier [<a href="#rid1">1</a>]. t-MNs are not considered a separate category of disorders in the ICC system. </p><p></p><p class="bulletIndent1">Cases of t-MNs with a mutated <em>TP53</em> (which encodes p53) are included in a new ICC category called Myeloid neoplasm with mutated <em>TP53</em> [<a href="#rid1">1</a>]. Cases that do not meet criteria for this category are described as either MDS, MDS/AML, AML, or MDS/MPN with "therapy-related" after the corresponding diagnosis.</p><p></p><p class="bulletIndent1">Further discussion of the ICC classification system is provided separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'International Consensus Classification (ICC)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World Health Organization 5</strong><strong><sup>th</sup></strong><strong> edition</strong> – World Health Organization 5<sup>th</sup> edition (WHO5) gives primacy to the relatedness of these disorders to prior treatment. However, within the category, it is recommended that a complete diagnosis be provided based on morphology and genetic features, and the descriptor "post cytotoxic therapy" is added to the relevant myeloid disease to distinguish them from myeloid disorders associated with germline/inherited gene variants. [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">Cases of AML, MDS, and MDS/MPN in patients with prior exposure to cytotoxic therapy are included in a new WHO5 category, entitled Secondary myeloid neoplasms, which also includes germline/inherited disorders. </p><p></p><p class="bulletIndent1">Further discussion of the WHO5 classification system is provided separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'World Health Organization 5th edition (WHO5)'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of t-MNs varies with the specific treatment and underlying disease. It has been estimated that t-MNs account for 10 to 20 percent of all cases of the corresponding myeloid malignancies [<a href="#rid3">3-6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Patients of any age can be affected, but the median age at diagnosis of a t-MN is 61 years [<a href="#rid7">7,8</a>]. The risk of t-MNs associated with alkylating agents and radiation therapy (RT) appears to increase with age, while the risk associated with topoisomerase II inhibitors appears to be constant across the age spectrum [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preceding condition</strong> – More than 80 percent of t-MNs are associated with treatment for a prior malignancy. It has been estimated that 70 percent of prior malignancies were a solid tumor, while 30 percent were an earlier hematologic malignancy [<a href="#rid3">3-5,9,10</a>]. The remaining 5 to 20 percent of cases arise in patients treated with cytotoxic therapy for a non-neoplastic disorder or who underwent autologous hematopoietic cell transplantation for a nonmyeloid neoplasm. </p><p></p><p class="bulletIndent1">A population-based study of more than 400,000 patients treated with chemotherapy in the United States (1975 to 2008) reported that, compared with the general population, there was a 4.7-fold increased risk (95% CI 4.4-5.0) for therapy-related acute myeloid leukemia (AML) [<a href="#rid11">11</a>]. The highest excess annual risks were observed after treatment for Hodgkin lymphoma (HL) and multiple myeloma (MM), while the lowest were after breast cancer. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease latency</strong> – Disease latency refers to the interval from first exposure to the cytotoxic agent until the diagnosis of t-MNs. Disease latency varies with the implicated agent(s). </p><p></p><p class="bulletIndent1">In one study, the incidence for therapy-related AML was highest in the first five years after treatment, but the risk subsequently declined [<a href="#rid11">11</a>]. After ≥10 years, there was no increased risk after treatment for a nonhematologic malignancy, but a three- to sixfold increased risk persisted for patients with a prior HL, non-Hodgkin lymphoma (NHL), or MM.</p><p></p><p class="bulletIndent1">In a single-institution study of 306 patients with a t-MN, 77 had a prior HL, 70 had an NHL, 24 had MM or another hematologic malignancy, 117 had various solid tumors, and 18 had nonmalignant diseases (primarily autoimmune diseases or kidney transplantation) [<a href="#rid12">12</a>]. Patients in this study had been treated with combined RT plus chemotherapy (139 patients), chemotherapy alone (121 patients), or RT alone (43 patients). Most patients treated with RT alone received radiation to large portals encompassing active bone marrow. Median latency for the entire population was 62 months, but it was longer in patients with nonmalignant primary diagnoses and in younger patients.</p><p></p><p class="bulletIndent1">Development of t-MNs after treatment for specific diseases is discussed in those topics.</p><p></p><p class="headingAnchor" id="H51744700"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>By definition, t-MNs occur in patients who were previously treated with DNA-damaging agents, such as cytotoxic chemotherapy or radiation therapy (RT). Designation as a t-MN does not prove causality in an individual case.</p><p>t-MNs may be a direct consequence of mutational events induced by cytotoxic therapy and/or by selection and expansion of treatment-resistant clones [<a href="#rid13">13-15</a>]. Various DNA-damaging treatments and underlying diseases are associated with the development of t-MNs, but certain individuals also have an inherited predisposition or other contributing factors. </p><p class="headingAnchor" id="H3112682758"><span class="h2">Causal agents</span><span class="headingEndMark"> — </span>Several categories of cytotoxic therapy have been most frequently associated with t-MNs. Disease latency varies with the type of therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkylating agents</strong> – Alkylating agents that have been associated with t-MNs include <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, nitrogen mustard, <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a>, <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_general" data-topicid="9992" href="/z/d/drug information/9992.html" rel="external">thiotepa</a>, and <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a>.</p><p></p><p class="bulletIndent1">t-MNs typically present five to seven years after initial treatment with alkylating agents or RT [<a href="#rid4">4,12,16-18</a>]. Two-thirds of cases are first recognized by evidence of myelodysplasia (usually trilineage dysplasia), marrow failure, and pancytopenia. The most common chromosomal findings involve complex abnormalities, deletion of 5q or 17p, and monosomies (eg, -7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topoisomerase II inhibitors</strong> – Implicated agents include <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9974" href="/z/d/drug information/9974.html" rel="external">teniposide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">daunorubicin</a>, <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="9343" href="/z/d/drug information/9343.html" rel="external">amsacrine</a>, and actinomycin. The malignancies usually present as acute myeloid leukemia (AML) and only rarely as other myeloid neoplasms.</p><p></p><p class="bulletIndent1">The latency with topoisomerase II inhibitors is generally one to three years after treatment, which is shorter than after alkylating agent therapy; antecedent myelodysplastic syndromes/neoplasms (MDS) is rare [<a href="#rid19">19-23</a>]. Topoisomerase II inhibitors are associated with breakage at topoisomerase II sites leading to abnormal recombination and balanced translocations; examples include <em>KMT2A</em> at chromosome 11q23.3, <em>RUNX1</em> at 21q22.1, or <em>RARA</em> at 17q21.2. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PARP inhibitors</strong> – PARP (poly [ADP-ribose] polymerase) inhibitors have been associated with an increased risk for t-MNs [<a href="#rid24">24</a>]. A meta-analysis that included 18 randomized placebo-controlled trials reported that PARP inhibitors increased the odds ratio 2.63-fold (CI 1.13–6.14) for MDS and AML; median latency from initial treatment to diagnosis was 18 months [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – t-MNs usually arise after RT that involves large fields that encompass active bone marrow. RT alone, RT plus chemotherapy (combined modality treatment), and radionuclide-linked agents have been associated with t-MNs. The latency period after RT is typically five to seven years [<a href="#rid16">16-18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – Antimetabolites (eg, thiopurines, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>) and antitubulin agents (eg, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10303" href="/z/d/drug information/10303.html" rel="external">vindesine</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>) have been implicated, often when they were administered with one or more of the agents listed above. <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> was excluded as a causal agent in the World Health Organization 5th edition [<a href="#rid2">2</a>], but its possible role remains uncertain. </p><p></p><p class="bulletIndent1">Latency periods with these other agents are less certain because many patients had exposure to multiple and/or sequential DNA-damaging agents.</p><p></p><p class="bulletIndent1">The role of agents such as <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, L-asparaginase, and radioisotopes is less certain. Growth factors, such as <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">filgrastim</a>, may facilitate emergence of a t-MN clone, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors", section on 'Possible stimulation of malignancy'</a>.)</p><p></p><p class="headingAnchor" id="H662906652"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>In many cases, t-MNs are thought to be the direct consequence of mutational events induced by cytotoxic therapy. In general, t-MNs are associated with adverse genetic lesions, and more than 90 percent show an abnormal karyotype. </p><p>Because t-MNs develop in only a small percentage of patients treated with these agents, the underlying pathophysiology is not well defined. The following mechanisms are thought to contribute to the pathophysiology of t-MNs:</p><p class="bulletIndent1"><span class="glyph">●</span>Inherited predisposition – Some affected individuals may have an inherited predisposition, such as a pathogenic variant in a DNA damage-sensing or repair gene (eg,<em> BRCA1/2</em> or<em> TP53</em>) or polymorphisms in genes that affect drug metabolism or transport [<a href="#rid26">26-28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selection for progression of aberrant clones – Cytotoxic agents can select for clones of cells that are relatively resistant to treatment. Such clones may reflect clonal hematopoiesis of indeterminate potential (CHIP) or a pre-existing population of chemotherapy-resistant cells.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CHIP refers to a clone of cells with a somatic mutation of a myeloid neoplasm driver gene with ≥2 percent allele frequency in a patient lacking a myeloid neoplasm or unexplained cytopenia. CHIP can be a precursor to a t-MN, and it may also occur as a consequence of cytotoxic therapy [<a href="#rid29">29</a>]. CHIP is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">"Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Expansion of a pre-existing chemotherapy-resistant myeloid clone may contribute to t-MN development [<a href="#rid30">30</a>]. As examples, hematopoietic stem or progenitor cells that carry mutated <em>TP53</em> or <em>PPM1D</em> may undergo positive selection by cytotoxic therapy. Mutations found at diagnosis of a t-MN have been identified at low frequency in blood or bone marrow specimens from many years earlier [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H3616162272"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of a t-MN varies, but most patients present with findings that resemble those of de novo acute myeloid leukemia or primary myelodysplastic syndromes/neoplasms. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H2893303898"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>A patient with a suspected t-MN should undergo clinical evaluation, laboratory studies, and bone marrow examination.</p><p>Evaluation for a t-MN should be performed in accordance with College of American Pathologists and the American Society of Hematology (CAP-ASH) guidelines [<a href="#rid32">32</a>] and European LeukemiaNet [<a href="#rid33">33,34</a>]. Additional details of the evaluation are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.) </p><p>It is important to evaluate the patient for a germline or inherited predisposition, especially in cases with mutated <em>PPM1D</em>, DNA-damage response genes, or other uncommon genetic findings. Germline conditions are especially likely in cases where the variant allele frequency (VAF) is approximately 50 percent or the VAF does not change at the time of remission.</p><p class="headingAnchor" id="H2207912513"><span class="h2">Clinical</span></p><p class="bulletIndent1"><span class="glyph">●</span>History reveals prior treatment with a cytotoxic agent for another malignancy or nonmalignant condition. The specific agents and period of exposure should be determined. </p><p></p><p class="bulletIndent1">The most common symptoms are related to pancytopenia, such as weakness, easy fatigue, fever, and/or excessive bleeding/bruising (eg, gingival bleeding, epistaxis, menorrhagia). Some patients have few or no symptoms; in such cases the diagnosis is based on laboratory findings alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination may reveal pallor, petechiae, or ecchymoses, but there may be no abnormal findings. Occasionally, a patient may present with splenomegaly or a myeloid sarcoma (chloroma).</p><p></p><p>The clinical presentations of de novo AML and MDS are described separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H1559428902"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Laboratory studies reflect findings associated with acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), or an MDS/myeloproliferative neoplasm (MPN). </p><p>The following laboratory studies should be performed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete blood count with differential leukocyte count</strong></p><p></p><p class="bulletIndent2">The complete blood count (CBC) and differential count typically reveal one or more cytopenias. Anemia is almost always present, and red blood cells (RBCs) are usually normochromic/normocytic or macrocytic (increased mean cell volume [MCV]) with poikilocytosis (elevated red cell distribution width [RDW]). </p><p></p><p class="bulletIndent2">Some patients have leukocytosis related to circulating blasts or other immature or dysplastic myeloid forms, while others may have leukopenia and/or thrombocytopenia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood smear</strong> – Microscopy resembles the corresponding AML, MDS, or MDS/MPN. </p><p></p><p class="bulletIndent2">Myeloid blasts, with or without Auer rods  (<a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">picture 1</a>), may be apparent in peripheral blood. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Peripheral blood'</a>.)</p><p></p><p class="bulletIndent2">There may be dysplasia with RBC abnormalities (eg, dyserythropoiesis)  (<a class="graphic graphic_picture graphicRef85882" href="/z/d/graphic/85882.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef85883" href="/z/d/graphic/85883.html" rel="external">picture 3</a>) [<a href="#rid12">12,35,36</a>], but some cases manifest few or no detectable abnormal forms in peripheral blood. There may be dysplasia in the neutrophil lineage, such as nuclear hyposegmentation (eg, Pelger-Huet anomaly)  (<a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">picture 4</a>) and/or hypogranular cytoplasm  (<a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Blood smear'</a>.)</p><p></p><p class="bulletIndent2">In cases of MDS/MPN, there may be abnormal mononuclear cells with features intermediate between myelocytes and monocytes  (<a class="graphic graphic_picture graphicRef85880" href="/z/d/graphic/85880.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemistries</strong> – Serum chemistries should include electrolytes, glucose, kidney function, and liver function tests.</p><p></p><p class="bulletIndent1">Patients can present with a range of metabolic and electrolyte abnormalities, some of which are due to a high turnover of proliferating leukemic cells (eg, hyperuricemia; hyperphosphatemia; lactic acidosis, elevated lactate dehydrogenase, and disturbances of potassium or calcium), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4510.html" rel="external">"Acute myeloid leukemia: Overview of complications", section on 'Metabolic abnormalities'</a>.) </p><p></p><p class="bulletIndent1">Tumor lysis syndrome is a medical emergency that should be suspected in patients with hyperphosphatemia, hypocalcemia, hyperuricemia, and/or hyperkalemia. (See  <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p>Characteristic laboratory findings associated with MDS, AML, and MDS/MPN are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Pathologic features'</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3655311762"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>Bone marrow aspiration and biopsy are required to diagnose a t-MN. </p><p>Studies should include microscopy, histochemical studies, immunophenotyping, and cytogenetic/molecular analysis, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Bone marrow biopsy and aspirate'</a>.)</p><p class="headingAnchor" id="H3746971341"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>Bone marrow cellularity is usually increased, but it may be normal or decreased, and there may be reticulin fibrosis [<a href="#rid35">35,37</a>]. The normal cellular components of the marrow may be mostly replaced by immature or undifferentiated blasts  (<a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">picture 1</a>), but there may be only modest infiltration by blasts or other abnormal forms. Megakaryocytes are frequently dysplastic and exhibit hypolobated or nonlobated nuclei and/or widely separated lobes.</p><p>Diagnosis and classification of t-MNs require determination of the percentage of myeloblasts in the bone marrow and blood, as described below. (See <a class="local">'Diagnosis and classification'</a> below.)</p><p class="headingAnchor" id="H3699335401"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>Flow cytometry is used to characterize the immunophenotype of a bone marrow specimen; immunophenotype can be determined using peripheral blood if there are adequate circulating aberrant cells. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – There are no unique or specific immunophenotypical findings associated with t-MNs, but flow cytometry is essential for identifying the blast immunophenotype and providing supportive evidence for dysplasia. Flow cytometry should be performed according to the standard methods proposed by the International Flow Cytometry Working Group of the European LeukemiaNet [<a href="#rid38">38,39</a>]. </p><p></p><p class="bulletIndent1">Myeloid antigens are often expressed aberrantly. Blasts usually express CD34 and pan-myeloid antigens (eg, CD13, CD33), but the expression of maturation-associated antigens (eg, myeloperoxidase) is variable [<a href="#rid40">40,41</a>]. Flow cytometry may also indicate hypogranularity of maturing neutrophils. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry</strong> – Staining of bone marrow may demonstrate abundant p53-positive cells in bone marrow, which correlates with mutation of <em>TP53</em> [<a href="#rid42">42,43</a>].</p><p></p><p class="headingAnchor" id="H1850296653"><span class="h3">Genetic findings</span><span class="headingEndMark"> — </span>Metaphase cytogenetic analysis of the bone marrow aspirate specimen must be performed. Most cases of t-MN have an abnormal karyotype, and cytogenetic findings may influence treatment, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122864.html" rel="external">"Therapy-related myeloid neoplasms: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetic abnormalities</strong> – More than 90 percent of cases of t-MN exhibit a clonal chromosomal abnormality [<a href="#rid44">44</a>]. Approximately two-thirds have unbalanced chromosomal aberrations, most often involving partial loss of 5q, loss of chromosome 7, or del(7q) [<a href="#rid10">10,12,18,45-48</a>]. Approximately 80 percent of cases with del(5q) also have abnormalities of 17p (usually indicative of loss of <em>TP53</em>). Loss of 5q may also be associated with del(13q), del(20q), del(11q), del(3p), monosomy 17 or del(17p), del(18), del(21), or gain of chromosome 8. </p><p></p><p class="bulletIndent1">Cytogenetic abnormalities in t-MNs may resemble those in de novo AML, but they differ in frequency. In one study, compared with patients with de novo AML, patients with a t-MN were less likely to have normal cytogenetics (10 versus 40 percent, respectively) and were more likely to have an unfavorable cytogenetic profile (46 versus 20 percent) [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">Cytogenetic abnormalities differ in t-MNs that arise after radiation therapy (RT) alone compared with t-MNs after chemotherapy exposure. One study compared t-MNs that arose after RT alone (47 patients) or after cytotoxic chemotherapy (with or without RT; 181 patients) with 222 patients who had de novo MDS or AML [<a href="#rid50">50</a>]. Patients with a t-MN after chemotherapy exposure had more high-risk karyotypic features and inferior survival compared with t-MNs after RT alone or de novo MDS or AML; there was no significant difference in survival or frequency of high-risk karyotypes between the RT and de novo groups. </p><p></p><p class="bulletIndent1">In a single-center study of 109 patients who developed a t-MN after receiving only RT, the most common cytogenetic abnormality was a clonal abnormality in chromosome 5 and/or 7 (45 percent of patients); other findings included a recurring translocation (14 percent), other clonal abnormalities (17 percent), and a normal karyotype (24 percent) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations</strong> – Mutations in <em>TP53</em> or <em>PPM1D</em> (a gene that encodes a regulator of p53) are more common in t-MNs than in de novo MDS or AML; these abnormalities are associated with inferior prognosis [<a href="#rid30">30,42,43,46,51,52</a>]. Mutations of <em>SRSF2</em>,<em> SF3B1</em>,<em> U2AF1</em>,<em> ZRSR2</em>,<em> ASXL1</em>,<em> EZH2</em>,<em> BCOR</em>, or <em>STAG2</em> are more also more frequent in t-MNs compared with de novo disorders [<a href="#rid45">45</a>].</p><p></p><p>Additional details of cytogenetic and molecular abnormalities in AML, MDS, and MDS/MPN are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Bone marrow biopsy and aspirate'</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Bone marrow examination'</a> and  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis", section on 'Molecular features'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>A t-MN should be suspected in patients with prior exposure to cytotoxic agents or radiation therapy (RT) for another condition who present with findings related to leukocytosis or cytopenias, circulating blasts, or other abnormal myeloid cells, as discussed above. (See <a class="local">'Clinical presentation'</a> above.) </p><p class="headingAnchor" id="H4222226767"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Diagnosis of t-MNs is based on documentation of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), or MDS/myeloproliferative neoplasm (MPN) in a patient treated with chemotherapy or RT for another malignancy or another disease (eg, an autoimmune disorder).</p><p>It should be recognized that although there are biologic, treatment, and prognostic differences between t-MNs and the corresponding myeloid malignancies, the primary diagnostic distinction is epidemiologic (ie, a history of exposure to a cytotoxic agent). Distinguishing a t-MN from a de novo myeloid malignancy is discussed below. (See <a class="local">'de novo myeloid neoplasms'</a> below.)</p><p>Excluded from a diagnosis of a t-MN are MPNs that progress to acute leukemia, blast phase of chronic myeloid leukemia, and evolution of de novo MDS to AML (so-called "secondary" AML) in the absence of cytotoxic therapy. In these settings, disease progression is considered part of the natural history of the primary disease. (See  <a class="medical medical_review" href="/z/d/html/4496.html" rel="external">"Overview of the treatment of chronic myeloid leukemia", section on 'Pretreatment evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'Malignancies and disease transformation'</a> and  <a class="medical medical_review" href="/z/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Transformation to acute myeloid leukemia'</a>.)</p><p>Diagnostic criteria for the corresponding de novo MNs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1122883809"><span class="h2">Classification</span><span class="headingEndMark"> — </span>The names and classification of t-MNs differ between contemporary classification schemes for hematologic malignancies: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Classification Consensus</strong> – International Classification Consensus (ICC) of myeloid neoplasms and acute leukemia </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World Health Organization 5th edition</strong> – The World Health Organization 5th edition (WHO5) classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms</p><p></p><p>Similarities and differences between the ICC and WHO5 systems are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.) </p><p class="headingAnchor" id="H2752460060"><span class="h3">International Classification Consensus</span><span class="headingEndMark"> — </span>The ICC designates t-MNs according to morphologic and genetic features as either MDS, MDS/AML, AML, or MDS/MPN, with the addition of "therapy-related" as a diagnostic qualifier [<a href="#rid1">1</a>].</p><p>Many t-MNs have mutated <em>TP53</em>. Cases that meet criteria for multihit (ie, bi-allelic) <em>TP53</em> mutations are included in the new ICC disease category, Myeloid neoplasm with mutated <em>TP53</em> [<a href="#rid1">1</a>]. Classification and categorization of cases that meet the criteria for Myeloid neoplasms with mutated <em>TP53</em> are described separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myeloid neoplasms with mutated TP53'</a>.)</p><p>Cases that do not meet multi-hit <em>TP53</em> mutation criteria are described as either MDS, MDS/AML, AML, or MDS/MPN with "therapy-related" after the corresponding diagnosis.</p><p class="headingAnchor" id="H3019576940"><span class="h3">World Health Organization 5th edition</span><span class="headingEndMark"> — </span>WHO5 gives primacy to the relatedness of these diseases to prior treatment rather than to the morphologic and genetic features [<a href="#rid2">2</a>]. As a result, cases of AML, MDS, and MDS/MPN in patients who were exposed to cytotoxic therapy are included in a new category, Myeloid neoplasms post-cytotoxic therapy (MN-pCT), which is a subset of Secondary myeloid neoplasms.</p><p>Designation as a MN-pCT is based on the medical history rather than the specific diagnosis. Cases must fulfill criteria for the specific myeloid neoplasm plus a documented history of chemotherapy or large-field RT for another condition. Cases are labeled with the most specific subtype of myeloid neoplasm, according to morphologic and genetic features, with "post-cytotoxic therapy" appended. Prior treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is not considered a qualifying exposure by WHO5.</p><p class="headingAnchor" id="H920611322"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of t-MNs includes the corresponding de novo myeloid neoplasms, other hematologic malignancies, and conditions associated with cytopenias.</p><p class="headingAnchor" id="H232900420"><span class="h2">de novo myeloid neoplasms</span><span class="headingEndMark"> — </span>Clinical features and laboratory findings of t-MNs and de novo myeloid neoplasms are similar and may be indistinguishable. t-MNs are distinguished from de novo myeloid neoplasms by a history of prior exposure to a cytotoxic agent for an unrelated disorder (eg, another malignancy or other condition). </p><p>Distinguishing a relapse of de novo acute myeloid leukemia (AML) from therapy-related AML that arose from treatment of the prior de novo AML can be challenging [<a href="#rid53">53-55</a>]. The distinction can be made in some cases by comparing the karyotype, mutation profile, and immunophenotype at relapse with those at the time of the initial diagnosis; emergence of a distinctly different karyotype or molecular profile suggests, but does not prove, a therapy-related origin rather than relapse/recurrence of the original leukemic clone.</p><p>Chronic myeloid leukemia (CML) is associated with <em>BCR::ABL1</em> (the Philadelphia chromosome; t(9;22)), and CML in accelerated phase or blast crisis may present with circulating blasts, cytopenias, and symptoms that resemble a t-MN. Although t(9;22) can occasionally be found in a patient with prior cytotoxic therapy exposure, the presence of <em>BCR::ABL1</em> excludes the diagnosis of a t-MN. (See  <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia"</a>.)</p><p>Details of the clinical manifestations and diagnosis of AML, myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2766955380"><span class="h2">Other hematologic malignancies</span><span class="headingEndMark"> — </span>Other hematologic malignancies, such as systemic mastocytosis (SM) can resemble a t-MN with circulating blasts, cytopenias, or symptoms related to pancytopenia. Therapy-related cases of acute lymphoblastic leukemia (ALL) have also been observed. </p><p>SM can be distinguished by the presence of aberrant mast cells in blood, bone marrow, skin, or other organs and is typically accompanied by manifestations of mast cell activation (eg, flushing, urticaria, diarrhea, abdominal cramping, wheezing, syncope). Clinical manifestations and diagnosis of SM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Additional evaluation and bone marrow biopsy'</a>.)</p><p>In the case of ALL or other lymphoid malignancies, circulating blasts exhibit lymphoid morphologic, histochemical, or immunophenotypic features rather than myeloid features. Diagnosis of ALL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a>.) </p><p class="headingAnchor" id="H2237114056"><span class="h2">Other causes of pancytopenia</span><span class="headingEndMark"> — </span>Aplastic anemia, myelofibrosis, nutritional deficiencies, medications, arsenic toxicity, and other disorders can cause pancytopenia. Some of these conditions can be associated with aberrant circulating cells that resemble myeloblasts. The distinction between t-MNs and other causes of pancytopenia is made by history, physical examination, laboratory studies, and bone marrow examination, as described separately. (See  <a class="medical medical_review" href="/z/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p class="headingAnchor" id="H1081405040"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116628.html" rel="external">"Society guideline links: Acute myeloid leukemia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116777.html" rel="external">"Society guideline links: Myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H12775415"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/681.html" rel="external">"Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Therapy-related myeloid neoplasms (t-MNs) refer to cases of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), or MDS/myeloproliferative neoplasms (MPN) that arise in patients who received cytotoxic chemotherapy or radiation therapy (RT) for another condition (eg, another malignancy or autoimmune disorder).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – t-MNs account for up to 20 percent of myeloid malignancies. They can present at any age, but the median age is the 60s. Most cases arise after treatment for a prior malignancy, but some cases present after treatment for a non-neoplastic disorder or after autologous hematopoietic cell transplantation for a nonmyeloid neoplasm. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – The most commonly implicated cytotoxic agents are alkylating agents, topoisomerase II inhibitors, PARP (poly [ADP-ribose] polymerase) inhibitors, and/or RT. The interval between treatment and disease development varies with the type of treatment. (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1">Because t-MNs arise in only a small percentage of patients who receive these agents, there may be predisposing conditions (eg, inherited variants in DNA damage-sensing or repair genes or metabolic pathways). In addition to direct DNA damage, cytotoxic treatment may select for outgrowth of pre-existent chemotherapy-resistant clones from multi-hit mutational events in hematopoietic stem cells. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – The clinical presentation is variable, but most patients present with findings that resemble those of the corresponding de novo myeloid neoplasms. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Clinical evaluation reveals exposure to cytotoxic therapy for an unrelated condition and findings associated with a myeloid neoplasm. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Laboratory studies and evaluation of bone marrow and blood are like those for the corresponding myeloid neoplasms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A t-MN should be suspected in a patient with prior cytotoxic chemotherapy or RT for another condition who has clinical or laboratory findings suggestive of a myeloid malignancy. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1">Diagnosis of a t-MN is based on pathologic findings of AML, MDS, or MDS/MPN in a patient with prior treatment with chemotherapy or RT for another condition. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Classification criteria and labels differ between contemporary classification systems (see <a class="local">'Classification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>International Classification Consensus</strong> – The International Classification Consensus classifies cases according to the disease category (ie, MDS, MDS/AML, AML, or MDS/MPN) with "therapy-related" added after the diagnosis. (See <a class="local">'International Classification Consensus'</a> above.)</p><p></p><p class="bulletIndent2">Many cases of t-MN meet criteria for Myeloid neoplasm with mutated<em> TP53</em>. Other cases are described as either MDS, MDS/AML, AML, or MDS/MPN with "therapy-related" after the corresponding diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>World Health Organization 5th edition</strong> – The World Health Organization classification 5<sup>th</sup> edition gives primacy to the relatedness of these diseases to prior treatment rather than to the morphologic and genetic features. Cases of AML, MDS, and MDS/MPN in patients previously treated with cytotoxic therapy for an unrelated disorder are included in the category of Myeloid neoplasms post-cytotoxic therapy (MN-pCT). (See <a class="local">'World Health Organization 5th edition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – t-MNs must be distinguished from the corresponding de novo myeloid neoplasms (ie, AML, MDS, MDS/MPN), other hematologic malignancies (eg, systemic mastocytosis), and other causes of cytopenias. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol 2015; 33:3641.</a></li><li><a class="nounderline abstract_t">Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137.</a></li><li><a class="nounderline abstract_t">Morton LM, Sampson JN, Cerhan JR, et al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014:1.</a></li><li><a class="nounderline abstract_t">Morton LM, Dores GM, Schonfeld SJ, et al. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncol 2019; 5:318.</a></li><li><a class="nounderline abstract_t">Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71:144.</a></li><li><a class="nounderline abstract_t">Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90:E80.</a></li><li><a class="nounderline abstract_t">Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121:2996.</a></li><li><a class="nounderline abstract_t">Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43.</a></li><li><a class="nounderline abstract_t">Voso MT, Falconi G, Fabiani E. What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood 2021; 138:749.</a></li><li><a class="nounderline abstract_t">McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017; 17:513.</a></li><li><a class="nounderline abstract_t">Schwartz JR, Ma J, Kamens J, et al. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nat Commun 2021; 12:985.</a></li><li><a class="nounderline abstract_t">Gundestrup M, Klarskov Andersen M, Sveinbjornsdottir E, et al. Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy. Lancet 2000; 356:2158.</a></li><li><a class="nounderline abstract_t">Larson RA. Therapy-related myeloid neoplasms. Haematologica 2009; 94:454.</a></li><li><a class="nounderline abstract_t">Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002; 33:331.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005; 352:1591.</a></li><li><a class="nounderline abstract_t">Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493.</a></li><li><a class="nounderline abstract_t">Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109:13.</a></li><li><a class="nounderline abstract_t">Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res 1992; 16:1113.</a></li><li><a class="nounderline abstract_t">Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 2013; 122:2807.</a></li><li><a class="nounderline abstract_t">Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 2021; 8:e122.</a></li><li><a class="nounderline abstract_t">Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C--&gt;T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803.</a></li><li><a class="nounderline abstract_t">Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol 2013; 26:309.</a></li><li><a class="nounderline abstract_t">Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 2016; 122:304.</a></li><li><a class="nounderline abstract_t">Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 2017; 18:100.</a></li><li><a class="nounderline abstract_t">Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518:552.</a></li><li><a class="nounderline abstract_t">Soerensen JF, Aggerholm A, Kerndrup GB, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv 2020; 4:885.</a></li><li><a class="nounderline abstract_t">Arber DA, Borowitz MJ, Cessna M, et al. Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med 2017; 141:1342.</a></li><li><a class="nounderline abstract_t">Jentzsch M, Grimm J, Bill M, et al. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant 2021; 56:936.</a></li><li><a class="nounderline abstract_t">Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140:1345.</a></li><li><a class="nounderline abstract_t">Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65:1364.</a></li><li><a class="nounderline abstract_t">Zhang L, Wang SA. A focused review of hematopoietic neoplasms occurring in the therapy-related setting. Int J Clin Exp Pathol 2014; 7:3512.</a></li><li><a class="nounderline abstract_t">Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol 2009; 132:410.</a></li><li><a class="nounderline abstract_t">Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26:1730.</a></li><li><a class="nounderline abstract_t">Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014; 28:1793.</a></li><li><a class="nounderline abstract_t">Arber DA, Slovak ML, Popplewell L, et al. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol 2002; 117:306.</a></li><li><a class="nounderline abstract_t">Orazi A, Cattoretti G, Soligo D, et al. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia 1993; 7:838.</a></li><li><a class="nounderline abstract_t">Cleven AH, Nardi V, Ok CY, et al. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol 2015; 28:552.</a></li><li><a class="nounderline abstract_t">Orazi A, Cattoretti G, Heerema NA, et al. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod Pathol 1993; 6:521.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125:1367.</a></li><li><a class="nounderline abstract_t">Shih AH, Chung SS, Dolezal EK, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013; 98:908.</a></li><li><a class="nounderline abstract_t">Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact 2010; 184:50.</a></li><li><a class="nounderline abstract_t">Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16:2366.</a></li><li><a class="nounderline abstract_t">Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18:120.</a></li><li><a class="nounderline abstract_t">Nardi V, Winkfield KM, Ok CY, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30:2340.</a></li><li><a class="nounderline abstract_t">Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 2017; 376:536.</a></li><li><a class="nounderline abstract_t">Ok CY, Patel KP, Garcia-Manero G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 2015; 39:348.</a></li><li><a class="nounderline abstract_t">Arana-Yi C, Block AW, Sait SN, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res 2008; 32:1043.</a></li><li><a class="nounderline abstract_t">Montesinos P, González JD, González J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28:3872.</a></li><li><a class="nounderline abstract_t">Imagawa J, Harada Y, Shimomura T, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood 2010; 116:6018.</a></li></ol></div><div id="topicVersionRevision">Topic 4506 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304885" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127174" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25174022" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30570657" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10745624" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653205" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412096" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12623843" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33876223" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835720" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapy-related myeloid neoplasms: when genetics and environment collide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33579957" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11191547" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336749" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11921269" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829541" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Insights into leukemogenesis from therapy-related leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290056" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10848777" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Topoisomerase II inhibitor-related acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1434747" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896412" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34945003" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347814" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397748" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of the inactivating 609C--&gt;T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507808" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The evolving challenge of therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641009" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27923552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487151" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32150606" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28225303" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33208914" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35797463" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3857944" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25120730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A focused review of hematopoietic neoplasms occurring in the therapy-related setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687318" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307178" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24919805" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11863228" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684797" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25412846" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8248107" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8248107" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25550361" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349305" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958752" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454741" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586477" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22585703" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28177873" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573287" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093651" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625122" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861459" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
